NACI Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine

The Novavax Nuvaxovid COVID-19 vaccine is the first COVID-19 recombinant protein subunit vaccine authorized in Canada. Novavax Nuvaxovid was authorized for use in adults ≥18 years of age by Health Canada on February 17, 2022. NACI's recommendations are aligned with the following goals of the Canadian COVID-19 Immunization Program, updated in October 2021:

• To enable as many Canadians as possible to be immunized as quickly as possible against COVID-19, while ensuring that high risk populations be prioritized;
• To minimize serious illness and overall deaths while preserving health system capacity;
• To reduce transmission to protect high risk populations.

Refer to the chapter on COVID-19 vaccine in the Canadian Immunization Guide for further information on COVID-19 vaccines.